TL;DR: Engage Bio is a Y Combinator Winter 2022 startup Potent, durable, and redosable non-viral genetic medicines, currently acquired with a team of 10.
Potent, durable, and redosable non-viral genetic medicines
Last verified:
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Built by LemStudio
Yes. Engage Bio was funded by Y Combinator in the Winter 2022 batch. Potent, durable, and redosable non-viral genetic medicines
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Engage Bio was part of Y Combinator's Winter 2022 batch.
Engage Bio has a team of 10 people according to Y Combinator's directory.
Engage Bio is currently listed as Acquired with a team of 10 in Y Combinator's directory.
Loading interactive view…